Cystic fibrosis transmembrane conductance regulator-related metabolic syndrome/cystic fibrosis screen positive, inconclusive diagnosis (CRMS/CFSPID)

Aditi Sinha, Kevin W. Southern

Source: Breathe, 17 (3) S45; 10.1183/20734735.0088-2021
Journal Issue: September

Congress or journal article abstractFull text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Aditi Sinha, Kevin W. Southern. Cystic fibrosis transmembrane conductance regulator-related metabolic syndrome/cystic fibrosis screen positive, inconclusive diagnosis (CRMS/CFSPID). Breathe, 17 (3) S45; 10.1183/20734735.0088-2021

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Atypical cystic fibrosis
Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-46-6, page=38
Year: 2006

Cystic fibrosis transmembrane conductance regulator pharmacotherapy
Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-46-6, page=88
Year: 2006

Identification of a new cystic fibrosis transmembrane regulator mutation in a severely affected patient
Source: Eur Respir J 2002; 19: 374-376
Year: 2002



Genotype/phenotype correlation of the G85E mutation in a large cohort of cystic fibrosis patients
Source: Eur Respir J 2004; 23: 679-684
Year: 2004



Targeting a genetic defect: cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis
Source: Eur Respir Rev 2013; 22: 58-65
Year: 2013



Cigarette smoke induces systemic defects in cystic fibrosis transmembrane conductance regulator (CFTR) ion transport
Source: Annual Congress 2013 –Cystic fibrosis: basic and applied science
Year: 2013

The cystic fibrosis transmembrane conductance regulator: state of the art
Source: Breathe 2008; 5: 163-167
Year: 2008

The cystic fibrosis transmembrane conductance regulator and its modulators: clinical implications
Source: Virtual Congress 2020 – Respiratory infections
Year: 2020


Cystic fibrosis and survival to 40 years: a study of cystic fibrosis transmembrane conductance regulator function
Source: Eur Respir J 2011; 37: 1076-1082
Year: 2011



High morbidity and mortality in cystic fibrosis patients compound heterozygous for 3905insT and ΔF508
Source: Eur Respir J 2001; 17: 1181-1186
Year: 2001



Lung function and early abnormality of glucose tolerance (GT) in cystic fibrosis (CF) patients
Source: Annual Congress 2013 –Cystic fibrosis: clinical problems and microbiology in adults
Year: 2013


CFTR: cystic fibrosis and beyond
Source: Eur Respir J 2014; 44: 1042-1054
Year: 2014



Lung function, weight, and sweat chloride responses in patients with cystic fibrosis and the G551D-CFTR mutation treated with ivacaftor: A secondary analysis
Source: Annual Congress 2013 –Cystic fibrosis: lung function and change of lung function in infants and children before and after treatment
Year: 2013


How organoids helped to discover cystic fibrosis transmembrane conductance regulator (CFTR) therapeutics and predict response to treatment
Source: International Congress 2016 – Closing the gap: novel translational research strategies
Year: 2016


Increased systemic inflammation in cystic fibrosis (CF) is associated with deterioration in lung clearance index (LCI)
Source: International Congress 2014 – Cystic fibrosis: genotypes, inflammation and microbiology
Year: 2014

Oral contraceptives do not appear to affect cystic fibrosis disease severity
Source: Eur Respir J 2013; 41: 67-73
Year: 2013



A three miRNA signature regulates the CF transmembrane conductance regulator (CFTR) in cystic fibrosis airway epithelium
Source: Annual Congress 2011 - Epithelial cells: role in health and disease
Year: 2011

The impact of genotype on clinical course of cystic fibrosis (CF) in adult patients
Source: Annual Congress 2013 –Cystic fibrosis: clinical problems and microbiology in adults
Year: 2013


MRI detects changes in structure and perfusion, and response to therapy in early cystic fibrosis lung disease
Source: International Congress 2014 – Cystic fibrosis: basic science, physiology and clinical aspects
Year: 2014

LATE-BREAKING ABSTRACT: Reducing inflammation in the lung by targeting the endothelial cystic fibrosis transmembrane conductance regulator with copper-tobramycin
Source: International Congress 2014 – Cystic fibrosis: genotypes, inflammation and microbiology
Year: 2014